This Fierce Biotech playbook discusses the potential of integrating Artificial Intelligence (AI) enabled solutions in pharmaceutical companies, particularly in small molecule drug discovery. Traditionally, the development of new drugs is a long and expensive process. AI tools could revolutionize this landscape by enhancing discovery efficiency, reducing costs and leveling the playing field for smaller companies.

AI technologies could save substantial resources in various drug discovery stages, including target identification, molecule design and clinical trial success rates. Notable achievements include the first AI-designed molecule entering human trials in early 2020, and the first AI-designed molecule targeting an AI-discovered disease entering Phase 1 trials in 2022.

If pharmaceutical companies manage to implement AI-enabled solutions correctly, they can expect substantial return on investment, primarily through improved resource efficiency and a higher success rate during drug development.

This playbook provides a comprehensive guide to integrating AI into existing drug discovery programs, emphasizing:

• The importance of strategic planning, cross-functional teamwork and trust-building
• Practical steps for adopting AI, from evaluating data infrastructure to selecting the right AI tools
• The logistical and financial considerations necessary for successful implementation